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Background: There is a need to shed light on the pathways through which complex interventions mediate their
effects in order to enable critical reflection on their transferability. We sought to explore and understand key
stakeholder accounts of the acceptability, likely impact and strategies for optimizing and rolling-out a successful
pharmacist-led information technology-enabled (PINCER) intervention, which substantially reduced the risk of
clinically important errors in medicines management in primary care.
Methods: Data were collected at two geographical locations in central England through a combination of
one-to-one longitudinal semi-structured telephone interviews (one at the beginning of the trial and another when
the trial was well underway), relevant documents, and focus group discussions following delivery of the PINCER
intervention. Participants included PINCER pharmacists, general practice staff, researchers involved in the running of
the trial, and primary care trust staff. PINCER pharmacists were interviewed at three different time-points during the
delivery of the PINCER intervention. Analysis was thematic with diffusion of innovation theory providing a
theoretical framework.
Results: We conducted 52 semi-structured telephone interviews and six focus group discussions with 30 additional
participants. In addition, documentary data were collected from six pharmacist diaries, along with notes from four
meetings of the PINCER pharmacists and feedback meetings from 34 practices. Key findings that helped to explain
the success of the PINCER intervention included the perceived importance of focusing on prescribing errors to all
stakeholders, and the credibility and appropriateness of a pharmacist-led intervention to address these
shortcomings. Central to this was the face-to-face contact and relationship building between pharmacists and a
range of practice staff, and pharmacists’ explicitly designated role as a change agent. However, important concerns
were identified about the likely sustainability of this new model of delivering care, in the absence of an appropriate
support network for pharmacists and career development pathways.
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Conclusions: This embedded qualitative inquiry has helped to understand the complex organizational and social
environment in which the trial was undertaken and the PINCER intervention was delivered. The longitudinal
element has given insight into the dynamic changes and developments over time. Medication errors and ways to
address these are high on stakeholders’ agendas. Our results further indicate that pharmacists were, because of
their professional standing and skill-set, able to engage with the complex general practice environment and able to
identify and manage many clinically important errors in medicines management. The transferability of the PINCER
intervention approach, both in relation to other prescribing errors and to other practices, is likely to be high.
Keywords: Qualitative evaluation, Randomized controlled trial, Pharmacist intervention, Primary careBackground
Medication errors (particularly those pertaining to prescrib-
ing and monitoring) are responsible for considerable mor-
bidity and, in some cases, mortality; the majority of these
are however believed to be preventable [1-3]. In the absence
of a robust evidence base on how to reduce the high disease
burden resulting from prescribing errors, there is an urgent
need to investigate new ways of enhancing prescribing
safety and reducing the risk of iatrogenic harm.
The highest rates of medication errors tend to be
found in patients taking multiple medications and also
in relation to certain drugs that are frequently associated
with preventable morbidity [4-9]. Reasons for these
errors have been studied in-depth over recent years and
this work has shown that both individual factors (for ex-
ample, knowledge about medication and slips in atten-
tion) as well as organizational factors (for example,
communication, work environment, workload, training,
supervision) are key contributory factors [10-14].
As most prescribing activity takes place in the general
practice (GP) environment, primary care has been the
focus of recent efforts to address the issue of medication
errors [15]. In this context, there is suggestive evidence
that pharmacist-led interventions in primary care may
reduce hospital admissions, but to date there has been
no confirmatory evidence from robust randomized con-
trolled trials in this setting [16].
Building on a body of descriptive, qualitative and pilot
work, we undertook a large complex intervention trial of a
pharmacist-led information technology-enabled (PINCER)
intervention compared with Simple feedback to re-
duce clinically important medication error rates. Details of
the PINCER trial design and findings have been
reported elsewhere [17,18], but in essence, data were
obtained from ‘at-risk’ patients from ten defined out-
come measures, identified through searches of GP com-
puter systems. The trial outcome measures are
summarized in Table 1. The interventions were delivered
in 72 practices in two locations in England. General
practices were centrally randomized to computer-
generated Simple feedback on at-risk patients (control
arm) or the PINCER intervention comprising feedback,educational outreach and dedicated support (interven-
tion arm). We considered it unethical to provide no
feedback to the control arm practices and provided these
practices with computer-generated feedback on at-risk
patients, with which they were free to intervene as they
saw fit. All practices therefore received at least some
form of intervention.
In the PINCER intervention, pharmacists were allo-
cated to work in practices for a period of three days per
week for up to 12 weeks. Pharmacists’ work involved
delivering computer-generated feedback to practice staff
obtained through electronic searches of individual prac-
tice systems conducted by other members of the re-
search team. Pharmacists used educational outreach and
root cause analysis techniques to identify potential
causes of clinically important errors in medicines man-
agement, and to assist practices in making changes to
patients’ medication. Simple feedback practices were
given computer-generated written feedback on clinically
important errors in medicines management and were
asked to make changes to identified patients’ medication
themselves in the 12-week intervention period. Quanti-
tative data were collected and analyzed at baseline and
six and 12 months post-intervention. Although the six
month juncture represented the main trial endpoint, we
were also interested in studying the sustained impact of
the PINCER intervention, hence our a priori decision to
also assess outcomes at 12 months post-intervention.
At both six and 12 months follow-up, patients in the
PINCER intervention practices were significantly less
likely to have a prescribing problem or a monitoring
problem (measured as composite outcome measures).
These findings are discussed at length in our related
paper [18]; the main results are summarized in Table 2.
The value of qualitative methods in complementing
complex randomized controlled trials by gaining an insight
into the causal pathways involved is increasingly recog-
nized in health services research [19-26]. For example, the
Medical Research Council (MRC) highlights the value of
mixed method approaches to evaluating complex interven-
tions, with a qualitative component running parallel to a
main trial investigating processes and issues surrounding
Table 1 Outcome measures in the PINCER Trial
Primary outcome measures The proportion of patients in each practice:
1. With a history of peptic ulcer being prescribed non-selective non-steroidal anti-inflammatory drugs
2. With a history of asthma being prescribed beta-blockers
3. Aged 75 years and older receiving long-term prescriptions for angiotensin-converting enzyme inhibitors
or loop diuretics without a recorded assessment of renal function and electrolytes in the preceding 15 months.
4. Proportions of women with a past medical history of venous or arterial thrombosis who have been
prescribed the combined oral contraceptive pill
Secondary outcome measures 5. Patients receiving methotrexate for at least three months who have not had a recorded full blood count
and/or liver function test within the previous three months
6. Patients receiving warfarin for at least three months who have not had a recorded check of their international
normalized ratio within the previous 12 weeks
7. Patients receiving lithium for at least three months who have not had a recorded check of their lithium levels
within the previous three months
8. Patients receiving amiodarone for at least six months who have not had a thyroid function test within the
previous six months
9. Patients receiving prescriptions of methotrexate without instructions that the drug should be taken weekly
10. Patients receiving prescriptions of amiodarone for at least one month who were receiving a dose of more
than 200 mg per day.
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[22,23]. Similarly, Bradley and colleagues have recently
argued that qualitative methods can help to explain quanti-
tative findings and therefore facilitate the design of more
effective future interventions [24]. A central component of
a qualitative evaluation of complex interventions is a focus
on the experiences and viewpoints of different stakeholders
over time.
In line with this thinking, we conducted an embedded
longitudinal multi-faceted qualitative inquiry. We hoped
that this would help us interpret the trial findings by
providing an insight into the social and organizational
context in which the trial was being conducted, shedding
light on the likely causal pathways through which the
pharmacist-led approach mediated its effects, and by
assessing the likely transferability of the PINCER inter-
vention [27-29]. Furthermore, we hoped to build on
existing literature that has, while recognizing the valueTable 2 Main findings from the trial in relation to primary ou
Outcome measure Six months follow-up
Patients with a history of peptic ulcer
being prescribed non-selective NSAIDs
(nonsteroidal anti-inflammatory drugs)
Significant reduction in error
intervention practices when c
Simple feedback practices (OR
Patients with a history of asthma being
prescribed beta-blockers
Significant reduction in error
intervention practices when c
Simple feedback practices (OR
Patients aged 75 years and older receiving
long-term prescriptions for ACE inhibitors
or loop diuretics without a recorded
assessment of renal function and
electrolytes in the preceding 15 months.
Significant reduction in error
intervention practices when c
Simple feedback practices (OR
CI, confidence interval; OR, odds ratio.of qualitative methods in complementing complex ran-
domized controlled trials, typically failed to combine
both quantitative and qualitative findings into an inte-
grated and meaningful whole [27,28].
Methods
Sampling
In order to obtain a sufficiently rounded understanding
of the contextual factors surrounding the delivery of the
PINCER intervention, a variety of key stakeholders were
purposively sampled from the two different geographical
locations in which the main trial was delivered [30,31].
The sampling strategy included approaching PINCER
pharmacists to identify practice staff from PINCER inter-
vention practices, while participants from Simple feedback
practices were recruited with the help of the research team
who had conducted the recruitment visits (in order to




0.58, 95% CI 0.38, 0.89)
Reduced error rates in PINCER
intervention practices when compared to
Simple feedback practices but no longer
significant
(OR 0.91, 95% CI 0.59, 1.39)
rates in PINCER
ompared to
0.73, 95% CI 0.58, 0.91)
Significant reduction in error rates in PINCER
intervention practices when compared to
Simple feedback practices
(OR 0.78, 95% CI 0.63, 0.97)
rates in PINCER
ompared to
0.51, 95% CI 0.34, 0.78)
Significant reduction in error rates in PINCER
intervention practices when compared to
Simple feedback practices
(OR 0.63, 95% CI 0.41, 0.95)
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gested further participants within their practice. A range of
practice staff was interviewed including GPs, practice man-
agers, nurses and administrative staff from both PINCER
intervention and Simple feedback control arms. Other par-
ticipants included regional Primary Care Trust (PCT) staff
and community pharmacists who were familiar with the
trial, as well as members of the research team involved in
running the trial.
Data generation
A flow diagram of the study design summarizing the
process of data generation and the different phases is
given in Figure 1. Data were collected by a designated
qualitative researcher leading on the qualitative evalu-
ation aspect of the trial (KC).
All six PINCER pharmacists were interviewed at three
different time-points during the delivery of the PINCER
intervention. This included when they had just started
working on the trial, when they had worked in a numberPhase 1 
20 semi-structured brief 
telephone interviews conducted 
at the beginning of the trial 
interventions 
Phase 2 
32 semi-structured in-depth 
telephone interviews conducted 
when the interventions were well 
underway 
Phase 3 
Six multi-disciplinary focus 
groups after the delivery of the 
interventions 
Figure 1 Flow diagram of the different phases of the
qualitative evaluation.of practices, and an exit interview on finishing their work
on the trial [30].
Qualitative data were collected through semi-
structured telephone interviews and multi-disciplinary
focus groups. Focus groups were conducted in partici-
pating PINCER and Simple feedback practices. Partici-
pants in both focus groups and interviews consisted of a
mix of pharmacists, GPs, practice managers, nurses,
administrative staff, PCT staff, and community pharma-
cists. Additional data were collected from pharmacist
discussion groups attended by PINCER pharmacists
giving them the opportunity to exchange experiences
and facilitated by the research team, notes of practice
feedback meetings made by pharmacists who were part
of the PINCER intervention, and diaries kept by the
pharmacists over a period of 12-18 months.
Brief telephone interviews were conducted at the early
stages in both arms of the trial (Figure 1: Phase 1), more
in-depth interviews were conducted when both the
PINCER intervention and Simple feedback were well
underway (Figure 1: Phase 2) and focus groups were
conducted when both the PINCER intervention and
Simple feedback had been delivered (Figure 1: Phase 3).
Interviews explored general perceptions of prescribing
safety in general practice, experiences and opinions of
the PINCER intervention and the Simple feedback con-
trol arm, sustainability of the intervention, and expecta-
tions for the future. Core questions from the topic
guides are summarized in Table 3.
Six focus groups were conducted; the main questions
related to the potential future roll-out of the PINCER
intervention (see Table 4).
Data analysis
Interviews and focus groups were transcribed verbatim.
Broad themes and sub-themes were identified employing
thematic analysis using NVivo7 software to aid the coding
process [32]. Transcripts and notes were analyzed one by
one, creating themes and sub-themes until no new themes
emerged. Data from meetings and diaries were checked
against the emerging thematic structure. Particular atten-
tion was paid to comparing themes identified across differ-
ent sources, professional groups, geographical locations
and intervention/control arm. In analyzing data, we drew
on key principles from the diffusion of innovations litera-
ture, which provided a valuable conceptual framework of
how innovations are adopted by individuals over time and
how these then spread through organizations [33,34].
The main researcher (KC) and AS met regularly to
discuss emerging findings; the credibility of the data and
the analysis was enhanced by close involvement and dis-
cussions with the wider research team. Results were
periodically fed back to the Trial Management Group
and to PINCER pharmacists in order to confirm the
Table 3 Core questions from interview topic guides
Questions relating to the
trial - experiences and opinions
How appropriate is the trial’s
design?
What are the perceived obstacles
to success?
Are there any concerns and how
could these be addressed?
What is going well and why?
What do participants expect in
relation to outcomes?
Questions relating to a potential
roll-out of the trial
Would this be acceptable?
How could this be constructed?
What could be done better?
More general questions in
relation to prescribing safety in
general practice
What are the main perceived
issues?
Can pharmacists play a valuable
role in addressing these?
How do they see the future?
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tative researcher (SS) re-coded brief and in-depth inter-
view transcripts and gave thorough feedback on the
preliminary analysis to the primary researcher (KC), who
then incorporated this in the write-up of the work. This
resulted in minor amendments to the emerging findings.
We continued with data generation until no new
themes emerged. This resulted in a general framework
capturing the essence of the data collected at each stage.
Careful attention was paid to the comparison and inte-
gration of different professional groups and interven-
tion/control arms (that is, PINCER intervention and
Simple feedback). This was accomplished through seek-
ing out deviant cases and actively exploring alternative
explanations. Careful attention was also paid to taking a
non-judgmental approach to all aspects of dataTable 4 Core questions from focus group discussions
The wider usability
of the trial
How might the trial interventions be
modified or adapted in order to
maximize their effectiveness when





strategies might be both acceptable
to stakeholders and effective in
reducing prescribing errors in
general practice?
Introduction of three potential
models emerging from brief interviews
including:
Simple feedback - practices themselves
setting up and conducting searches on
a monthly basis
Training practice staff to provide
relevant clinical input
Pharmacist interventiongeneration, as the issue of prescribing errors was viewed
as a potentially sensitive topic. At the time of the initial
round of data collection, none of the participants (except
one pharmacist) had had any contact with the researcher
beforehand. It was hoped that this anonymity also facili-
tated disclosure of potential barriers and/or problems.
Ethical considerations
Ethical approval was obtained from the Nottingham 2 Re-
search Ethics Committee (Reference Number: 05/Q2404/
26) and local research management approvals were
obtained. Advanced disclosure and honorary contracts
were obtained prior to the study. All participants gave writ-
ten informed consent and had the opportunity to withdraw
from the study at any time. Transcripts were anonymized
and any identifiable information was kept in a locked cabi-
net in a locked office by the researcher collecting the data.
Results
A full description of the qualitative dataset for each
study phase can be viewed in Table 5. Overall, we col-
lected and analyzed data from 52 semi-structured tele-
phone interviews; six pharmacist diaries, notes from four
pharmacist discussion groups, feedback meetings in 34
practices, and six focus group discussions.
The study indicated that the PINCER intervention had
considerable credibility among stakeholders. Face-to-face
and regular interaction between the pharmacist and
practice staff was reported to be important. However,
the study also identified some important tensions relat-
ing to some of the outcome measures investigated, inte-
gration of the pharmacist into the practice team and the
nature of pharmacists’ work. Participants also pointed to
the important role of local health communities (concep-
tualized as practices in close geographical proximity to
each other) in relation to any future potential roll-out.
These issues are considered in detail below and are
structured along the following key themes:
 Credibility of the issue being addressed and the
PINCER intervention
 Regular interaction
 The nature of outcome measures and the resulting
way they are addressed in practices
 Integration of pharmacists into the practice team
 The nature of pharmacists’ work
 The likely central role of local health communities
in extending the PINCER intervention into routine
models of care.
Credibility of the issue being addressed and the
PINCER intervention
All GPs and their teams recognized that prescribing errors
were an important and potentially preventable problem
Table 5 A description of the full qualitative dataset for
each study phase
Phase 1 • 23 participants were invited to take part including
all six PINCER pharmacists, seven GPs, six practice
managers, two researchers and two PCT prescribing
leads.
• Three participants were excluded as they either
felt unqualified to answer questions or did not
return the researcher’s calls.
• Additional data were collected from two facilitated
pharmacist discussion groups at which the qualitative
researcher took notes.
Phase 2 • 37 participants were invited to take part
including all PINCER pharmacists (each interviewed
twice), 11 GPs, nine practice managers, two
community pharmacists, five nurses and four
prescribing leads.
• Five participants declined to participate,
mainly due to time constraints.
• Further data were collected from two audio-
taped pharmacist facilitated meetings. One was
facilitated by the trial coordinator with the qualitative
researcher taking notes. The other was designed
as an informal focus group, with the qualitative
researcher facilitating and the trial coordinator taking
notes.
• Additional qualitative data consisted of notes
of practices meetings made by pharmacists during
the delivery of the PINCER intervention and six
pharmacist diaries.
Phase 3 • Six focus groups were conducted with a total of
30 participants.
• Four focus groups were with practice staff from
practices in PINCER intervention and Simple
feedback practices including four practice managers,
one assistant practice manager, ten GPs, two nurses,
two data quality officers, one administrative staff,
one junior doctor, and one medical student.
• One telephone focus group was conducted with
PINCER pharmacists.
• One focus group with PCT staff in location 2 and
one interview with a member of the PCT in
location 1 (including Medical Advisors, professions
involved in medicines management, and those
from clinical and pharmaceutical backgrounds).
• The research team initially approached practices
that were recommended by the PINCER pharmacists
and those that had reduced numbers of patients
in relation to the outcome measures at follow-up.
However, due to a lack of willingness to participate,
it was decided to widen the sampling strategy and
therefore almost all practices that had participated
in the trial were subsequently approached. The
most commonly mentioned reason for refusing was
that practices were busy and felt that they had already
given up a lot of their time for the trial.
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centered intervention was a credible solution.
‘I think pharmacists are obviously much, much
better informed than we are er, and although actually
often maybe some of the hospital specialists wouldhave ideas about that they can be very idiosyncratic
in their ideas with things so it’s actually pharmacies
[sic], Pharmacists will tend to often be a lot more
evidence based in what they’re telling us and will have
looked into it in a bit more detail rather than their
own personal preferences. So it’s almost a more, I
think it’s almost a more reliable source of
information about drugs when we’re trying to make
decisions about whether we’re needing to alter
our practice.’
(GP 2, PINCER intervention practice, Focus Group 1,
Location 1).
‘Erm, certainly, erm, makes us more aware of erm,
one or two areas like beta-blocker, eye drops, erm,
I think some of us were not aware of, that they,
that there could be a problem with asthmatics
for example.’
(GP, PINCER intervention practice, Brief Interview 5,
Location 1).
Pharmacists in all PINCER intervention practices were
therefore highly valued and given the authority to ad-
dress many of the issues identified themselves. Both the
PINCER intervention and the Simple feedback control
arm were viewed as minimally disruptive in the busy
general practice environment, and most practices were
willing, and in some cases positively inclined, towards
having their databases periodically interrogated. The
trade-off or relative advantage between disruption and
identifying potentially serious errors was considered ac-
ceptable by the majority of practice staff.
Interviewer: I mean would that be something that
you think would be useful on a regular basis, on an
on-going basis to have some sort of audit like that.
I mean I would be quite interested to know whether,
you know, sort of just having sort of, you know, say
the searches run maybe every six months or
something like that. Would that be anything that
would be of interest to you?
GP: I think so yes. It would be of interest and I think
also it’s important from a patient safety point of view
so again if it’s unobtrusive and it’s a manageable
workload, then yes. If it’s all set up just keep
running it.
(GP 1, Simple feedback practice, Focus Group 2,
Location 1).
Regular interaction
Practice staff, and GPs in particular, believed that it was
important for a designated person to drive through any
changes that needed to be made (that is, the pharmacist
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going face-to-face contact between pharmacist and prac-
tice staff in PINCER intervention practices was
particularly valued.
‘But I think you can’t discount the human-human
interaction you get when someone cajoles you and
says, you know, says to you, ‘You really should be
doing this, it’s just a little job to do it’. It’s so much
better than a little email going ‘ping’. Email from
automatic pharmacist in some other place, they’re
somewhere else, would you please look at this. It’s just
not quite the same. I don’t know if that’s, in fact does
that matter, that we should be professionals, we
should do it anyway but we’re all human beings
and. . .because it isn’t just the numbers that motivate
people the human interaction is also what makes
people think well we ought, we really ought to do
something about this.’
(GP 2, PINCER intervention practice, Focus Group 2,
Location 1).
The lack of ongoing pharmacist input may also explain
the attenuation in all primary outcome measures at the
12 month assessment point (Table 2). Similarly, Simple
feedback practices were not given any further support,
making the implementation of changes suggested by the
educational material more dependent on key individuals
from within the practice to drive change. In most prac-
tices, these individuals appeared to be practice man-
agers, who took on the responsibility for organizing the
trial in the practice and driving changes forward.
Interviewer: And your role as a Practice Manager,
how would you describe that?
Practice Manager: Far reaching and wide ranging.
And, do you mean in terms of the PINCER Trial?
Co-ordinating it. From the practice point of view and
liaising with the hospital. . .I have met with the erm,
[name] and I’ve met with Professor, what’s his name?
Professor [name]. I liaised with them and arranged
meetings with my chief erm, my senior partner. I’ve
met with the software chap that did the reports, erm
and I’ve got the reports on my PC [personal
computer] and I liaise with the doctors about
actioning whatever has come out of those reports.
(Practice manager, Simple feedback practice, In-depth
Interview 11, Location 1).
However, the busy practice environment meant that
there were often conflicting priorities within practices.
‘I think they’ve got so many priorities and in that
particular case they were a single-handed practiceerm, so many priorities that erm, some of the issues
that, you know, with PINCER such as monitoring
erm, are possibly not top of the list.’
(Trial Pharmacist, Brief Interview 9, Location 2).
The nature of outcome measures and the resulting way
they are addressed in practices
The biggest reductions in the number of errors were in
relation to failures of drug monitoring (see Table 2). This
may have been due to pharmacists helping practices to
establish more effective mechanisms of communication
between primary and secondary care, which has repeat-
edly been recognized as an important problem in both
the United Kingdom and worldwide [35,36].
‘I think what we really should be taking forward is
this shared care which is quite a worry, you know, the
hospital are doing one thing and we’re doing another
and we’re supposed to be sharing the care. We’re
prescribing the medication but we’re not getting to
know the results from the hospital.’
(Nurse, PINCER intervention, In-depth Interview 10,
Location 1).
Nevertheless, we also identified some tensions across
practices that may have impacted on effectiveness. For
example, not all ‘errors’ were necessarily seen as failings
by clinicians. A particularly prominent example here was
in relation to patients with a history of asthma being
prescribed beta-blockers. Although this outcome was
significantly reduced at both six and 12 months,
many GPs believed that individualized patient-based
risk assessments needed to be made. This led GPs
in some instances to continue prescribing the beta-
blocker, over-ruling pharmacists’ advice on the basis
of clinical experience and in-depth knowledge of the in-
dividual patient.
‘GPs felt it was difficult to comment without knowing
the identity of the patients and their history. The issue
of risk/benefit for patients with CHD (coronary heart
disease) was raised. Also discussion around patients
identified as having ‘history of asthma’ which may
have arisen when notes were summarised based on
e.g. a single prescription many years ago for a
salbutamol inhaler prescribed for a severe chest
infection.’ (From pharmacist feedback sessions).
Integration of pharmacists into the practice team
Another source of concern related to pharmacists’ sense
of isolation, as in many cases they felt they were not ef-
fectively integrated into the practice team. The relatively
short time period (three days per week for up to
12 weeks) spent in individual practices was stated to be
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and sustaining meaningful clinical relationships by
all PINCER pharmacists. In addition, the location
of the pharmacist while undertaking work within the
PINCER intervention practices was raised as a concern
by some and contributed to feelings of isolation in
these individuals.
‘Erm, it can be a little bit lonely being the only
pharmacist working in a GP practice for, you know, a
couple of days. Erm, especially when you’re only there
temporarily. If you were there permanently and you
were really, really were part of their team, part of the
payroll then it would be different. But because you are
only there twelve weeks you don’t fully integrate into
their team. Erm, you know, it’s hard, I mean when we
come to work, we all come to work for money
obviously but, you know, you also want to build
relationships with the people that you work with and
when you’re moving on to somewhere new every
twelve weeks you don’t get that element of it I
suppose.’ (Trial Pharmacist, Brief Interview 8,
Location 2).
Recognizing this issue, the research team arranged
regular trial pharmacist discussion groups giving phar-
macists the opportunity to exchange experiences. How-
ever, although this was found to help reduce feelings of
isolation, other contributing factors were more difficult
to address; for example, the way pharmacists were
accommodated in the practices. Most pharmacists re-
peatedly reported having to work in busy locations such
as the reception area, move desks several times a day,
not having an identified work station or having to work
in a room remote from the main practice.
‘Some days there has been nowhere at all for me to
work and I have had to work in the tearoom –
difficult as people are coming in and out and there is
no computer access.’ (Pharmacist diary, Pharmacist 2)
‘I had very little to do with GPs/nurses. Was given a
room in the attic, so did not see anyone during the
day, unless I came out of my room to make tea/coffee
etc.’ (Pharmacist diary, Pharmacist 6)
The nature of pharmacists’ work
All PINCER pharmacists also raised issues with work
satisfaction. These included reports of missing direct pa-
tient contact and a feeling that their work for the trial
was frustrating at times as often problems encountered
in practices were beyond the scope of their trial work.
There was also a general concern among most that thedelivery of the same standardized PINCER intervention
was repetitive and not offering the desired flexibility of
tailoring outcomes and interventions to meet either their
own needs or the broader needs of participating prac-
tices. In addition, the perceived uncertainty surrounding
job security with pharmacists being employed on tem-
porary contracts was viewed as inhibiting a more stable
and (importantly) long-term relationship between phar-
macists and practice staff.
‘I don’t think people left the job because they felt it
boring, I think it was circumstantial that, and you
know, with the best will in the world however exciting
this job was, and I don’t think it’s the most exciting
job I’ve ever had but it’s certainly not awful, I don’t
think any of us have thought it was awful at all. I
think sometimes it can be a bit monotonous but any
job is monotonous, I mean I’d be saying exactly the
same practice work can be monotonous, so don’t
know, sort of unless you’re having patient contact
and that was just never going to be feasible in this
study, I think it was just, because it’s just contracts
and, you know, you’ve got to have a job when this
ends and unfortunately you can’t always time it
that it happens exactly when you want it to.’
(Pharmacist 1, Focus Group).
The likely central role of local health communities in
extending the PINCER intervention into routine
models of care
We developed insights into how the PINCER interven-
tion could be incorporated into routine practice, with
most practice staff and pharmacists suggesting that
PINCER pharmacists’ work could be incorporated into a
primary care pharmacist role. Currently, most PCTs em-
ploy pharmacists to work with selected practices in rela-
tion to medicines management, and participants
believed that the outcome measure searches and change
management activities could be incorporated into this
work. However, with the abolition of PCTs in England
by April 2013, primary care commissioning responsibi-
lity is being transferred to the newly formed general
practice clusters known as Clinical Commissioning
Groups [37]. These are increasingly responsible for com-
missioning services of primary care pharmacists and,
therefore, in terms of potential roll-out of the PINCER
intervention, it would be the Clinical Commissioning
Groups that would be employing pharmacists to work
with their cluster practices.
Although some drawbacks were acknowledged and the
extent of involvement may need further consideration,
the primary care pharmacist model was advocated re-
peatedly in focus groups as it would allow for adequate
leadership, skill-base and support/training structures.
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issues with work satisfaction raised by PINCER
pharmacists.
In line with the perceived general importance of
incentives, the recommendation to use the Quality and
Outcomes Framework (QOF) was also proposed by
some GPs [38].
GP 1: I’m just wondering whether you could link it to
QOF because, you know, in the QOF there’s a specific
indicator around is it one or two or three prescribing,
three prescribing initiatives. . . And whether or not
you could link one of those initiatives to, in particular
to a patient safety aspect of prescribing. . . Might be a
way to start and creep with it. (. . .)
Interviewer: . . .So can I ask you now which one
would you choose after discussing, or if you can think
of any more please erm, let us know but er, which one
would you go for?
GP 1: If we had to mainstream it and we were really
serious about making it work then I think I would go
with the PCT involvement model.
Practice Manager: Link it to QOF think that would be
a wonderful way to take it forward.
GP 1: Yeah.
(Simple feedback practice, Focus Group 2, Location 1)
Pharmacists recommended that, in order to allow for
more flexibility, pharmacists’ involvement could be clus-
ter based (or in the future Clinical Commissioning
Group-based), with one pharmacist looking after a group
of practices. This fits in well with the national drive to
give local health communities more autonomy [39].
Interpreting data in the light of the existing
theoretical literature
Both Roger’s work on the diffusion of innovation and
Greenhalgh’s work on the diffusion of innovation in
health service organizations proved helpful in interpret-
ing our findings [33,34]. These frameworks helped to
conceptualize the importance of perceived innovation
attributes and the role of key individuals in facilitating
diffusion of the PINCER intervention (conceptualized as
an innovation) across healthcare organizations.
The perceived value of the PINCER intervention can
be viewed in terms of what Rogers refers to as ‘relative
advantage’ and ‘compatibility’ [34]. Relative advantage, is
the extent to which the innovation is seen as better than
current practice. Compatibility is the extent of agree-
ment between the innovation and individual (or
organizational) values and beliefs. Patient safety is clearlyan organizational priority and optimal levels are an as-
piration, making the trial interventions compatible.
However, in order for interventions to be compatible
they also need to be acceptable to both individuals and
settings where they are implemented (in this case GP
practices) and those delivering them (in this case phar-
macists). In the healthcare setting, studies investigating
the predictive power of these two innovation attributes
and adoption behavior have been mixed [40-42]. Al-
though some have suggested that diffusion of innova-
tions in healthcare is slow if it involves acquiring new
skills [40], our work clearly supports the view that adop-
tion is more influenced by the perceived improvements
in patient safety [42].
‘. . .you find out something and we are doing it and
know intentionally it will be a good thing to know
that, why we shouldn’t be doing that. (. . .) Yeah, well
it will be effective because you are flagging the
patients out who’ve been prescribed perhaps
inappropriately or unintentionally the things they
shouldn’t prescribe where they can cause more
complications to them. (. . .) What will I, will be
actually alert, you know, next time we prescribe other
things. . .’
(GP, Simple feedback practice, Brief Interview 6,
Location 2)
PINCER pharmacists may be viewed as ‘change agents’.
In the diffusion of innovations literature, these are indi-
viduals who influence clients’ innovation decisions in a
direction deemed desirable by a ‘change agency’ [34]. It
is the change agency’s aim to implement the innovation
with a focus on the collective goals of the social system
(here to improve prescribing safety). Our findings sup-
port the notion of the important role of pharmacists as
change agents, as well as the importance of a good per-
sonal relationship and ongoing face-to-face contact be-
tween change agents and clients (that is, practice staff )
in facilitating adoption of innovations in primary care
settings [33,34,43-45].
GPs are local ‘opinion leaders’ [46]. Their involvement
is therefore clearly important for the successful adoption
of innovations as any apprehensiveness on their part in
this respect clearly has a high chance of influencing
other members of the practice team [46-48]. Although
Rogers argued that ideally the change agent should har-
ness the influence of opinion leaders, the nature of this
relationship remains under-researched [34]. In our trial,
the pharmacist as the change agent had the potential to
influence opinion leaders, but this was to a large extent
dependent on an effective working relationship between
the pharmacist and the GP. If this was not the case, and
this crucial relationship is characterized by infrequent
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to the change agent’s efforts, it could serve to act as a
major barrier to the diffusion of the innovation. Such re-
lationship considerations may have contributed to phar-
macists reporting experiences of difficulties in getting
GPs to, on occasions, make prescribing changes.
Practice managers frequently played the role of a
‘change aide’ in working with the pharmacist to facilitate
the interventions. This was often expressed in terms of
providing a link between the pharmacist and GPs
and helping the pharmacist to engage more with GPs
so that they would complete actions forms. Therefore,
systematically harnessing the practice manager’s influ-
ence might contribute to maximizing the impact of the
PINCER intervention.
‘Well if it’s something related to the surgery or
practice or my working then I ask the practice
manager, he like, some of the doctors, what happened
was I left some of them envelopes with some action
plans in them. When I went back the next week they
were still there, the doctors hadn’t picked them up or
some of them were a bit lazy picking their work out
of the pigeon holes and so basically the practice
manager said, ‘I’ll sort it out, don’t worry’. Then
he’s going to go and nag them now with the
envelopes.’
(Trial Pharmacist, In-depth Interview 6, Location 2).
Discussion
The PINCER Trial represents one of the world’s first
successful efforts at clearly establishing the effectiveness
of a complex pharmacist-led information technology-
enabled intervention, aiming to improve prescribing
safety in primary care [18,49,50]. This embedded longi-
tudinal evaluation has provided important insights into
why the PINCER intervention was so effective [51,52].
Nevertheless, some trends of improvement were also
observed in Simple feedback practices, highlighting the
important role of motivational issues in initiating and
sustaining change. Important contributory factors
included the GPs’ perceived importance of the clinical
interventions and the perceived appropriateness of a
pharmacist-based approach to address this issue. Central
to this was ongoing face-to-face contact between phar-
macists and practice staff. However, pharmacists also
expressed some concerns about the likely sustainability
of the pharmacist intervention model in the absence of
an appropriate support network and career development
pathways for pharmacists. Incorporating the PINCER
pharmacists’ role into routine local primary care phar-
macists’ work may provide a solution to these issues.
Our work indicates that this could for example be taken
forward by Clinical Commissioning Groups employingpharmacists to work with their cluster practices per-
forming outcome measure searches and change manage-
ment activities routinely.
Strengths and potential limitations of the present study
This embedded qualitative evaluation has generated an
in-depth nuanced account of the underlying processes of
the interventions under investigation. Data were longitu-
dinally collected from a range of sources (participants
and geographical locations), through a variety of data
collection methods (interviews, documents including
diaries, and focus groups), thereby allowing us to trace
developments over time and develop personal relation-
ships with participants, which possibly allowed franker
discussions than might have otherwise been the case
[53,54]. The longitudinal nature of the inquiry enabled
us to gain insights into how changes were initiated and
sustained over time, helping to take into account the
likely role of initial enthusiasm for initiating changes
combined with the everyday reality of sustaining them.
Similarly, pharmacists’ accounts over time revealed that
although initially PINCER intervention work was viewed
as interesting, there was, with time, a degree of monot-
ony associated with the role. Trustworthiness of the
study was increased through a second qualitative re-
searcher examining the interview transcripts and
reports, as well as having constant input from the
extended research team.
Although participating practices were larger and more
likely to be training practices than non-participating
practices, they were not atypical in any key respects.
Similarly, PINCER pharmacists came from a variety of
backgrounds (some with primary care experience and
some without, some with higher degrees and some with-
out) and seemed to be representative of the general
practice pharmacist population.
However, there are also some limitations to our study.
Practices are encouraged to improve prescribing safety
through the QOF, which is part of the General Medical
Services National Health Service Contract introduced in
April 2004 [38]. This framework includes a list of indica-
tors of practice performance that determine practice
payments with the help of a point system. One of these
indicators relates to the quality and safety of prescribing.
This may have influenced our results in both PINCER
intervention and Simple feedback control arms as prac-
tices may have addressed the issues identified as being
motivated by the framework rather than by the PINCER
intervention. Alternatively, framework indicators may
take priority over trial outcome measures as the frame-
work is closely related to payment incentives.
Our study has supported the value of telephone inter-
views in reaching geographically scattered individuals
with busy work schedules [55,56]. However, the most
Table 6 Potential questions for future research
Questions How can pharmacists (or other healthcare professionals)
be integrated more efficiently into established care
teams? How can multi-disciplinary collaboration be
more effective?
What other effective incentives may be viable to exploit
in primary care (other than financial incentives)?
How can audit and feedback techniques be refined to
include feedback of the impact of the interventions?
How can a more positive and close relationship
between pharmacists and GPs be fostered?
How can we design interventions that target all key
players and a range of practice staff?
Which intervention types are appropriate for which
practices? Is effectiveness influenced by practice
characteristics?
How can macro issues be addressed, particularly
communication issues with secondary care and
nursing homes and polypharmacy?
How exactly may the suggested community-based
pharmacist model be implemented into routine care?
To what extend can we allow for flexibility in this context?
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interviewer cannot respond to non-verbal cues of parti-
cipants. Also, questions are more easily misunderstood
on the telephone. Conversely, the anonymity of this
method of data collection might have facilitated disclos-
ure about a sensitive topic such as prescribing and medi-
cation errors.
The focus groups clearly complemented the inter-
views, mainly because it was possible to gain a deeper
understanding of the group dynamics and a range of
(potentially differing) viewpoints among participants
[57]. On the other hand, participants in the focus groups
may have been inhibited in expressing their personal
opinion due to the presence of others. Therefore, it is
common practice in qualitative methods to use inter-
views and focus groups in combination [58].
Implications for policy, practice and research
The findings from this work raise the question of
whether there is now need to implement more wide-
spread use of pharmacists in the primary care setting to
reduce potentially preventable medication errors. We
have provided a starting point for the conceptualization
of this model and outlined some issues that would need
to be addressed to maximize its effectiveness and accept-
ability among key stakeholders. We summarize potential
areas for further work based on our findings in Table 6.
Conclusions
Our study clearly supports the value of qualitative evalu-
ation methods in complementing randomized controlled
trials of complex interventions. Overall, the interven-
tions were delivered as planned and stakeholdersperceived them as valuable. This was particularly so in
the PINCER intervention arm. There was also a distinct
feeling that pharmacist intervention could be incorpo-
rated into the routine work of practice pharmacists
employed by the National Health Service to reduce pre-
scribing errors.
The most important factor distinguishing this pharma-
cist intervention from other interventions to reduce clin-
ically important errors in medicines management in
general practice appeared to be the face-to-face contact
with practice staff and the designated role of the
pharmacist as a change agent. Diffusion of Innovation
Theory provided a useful theoretical background and
has helped to integrate the current findings with the
existing literature.
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